SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 10-QSB
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 2007 | Commission file number 0-16416 |
MICRO IMAGING TECHNOLOGY, INC.
(Formerly, Electropure, Inc.)
(Exact name of registrant as specified in its charter)
California | 33-0056212 | |
(State or Other Jurisdiction of Incorporation or Organization) | (IRS Employer Identification No.) |
970 Calle Amanecer, Suite F, San Clemente, California 92673
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (949) 485-6006
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $0.01 per share
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes o No x.
At September 12, 2007, 30,065,781 shares of the Registrant’s stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE: NONE
Micro Imaging Technology, Inc. and Subsidiaries
(A Development Stage Company)
Condensed Consolidated Balance Sheet
(Unaudited)
July 31, | October 31, | ||||||
2007 | 2006 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash | $ | 127,366 | $ | 13,349 | |||
Inventories | 35,978 | - | |||||
Prepaid expenses | 12,386 | 12,587 | |||||
Total current assets | 175,730 | 25,936 | |||||
Fixed assets | 102,288 | 111,388 | |||||
Total assets | $ | 278,018 | $ | 137,324 | |||
LIABILITIES AND STOCKHOLDERS' DEFICIT | |||||||
Current liabilities: | |||||||
Trade accounts payable | 69,630 | 88,392 | |||||
Accounts payable to officers and directors | 48,000 | 32,229 | |||||
Accrued payroll | 20,144 | 117,246 | |||||
Other accrued expenses | 36,419 | 395,850 | |||||
Redeemable convertible preferred stock, $0.01 par value; 2,600,000 shares authorized, issued and outstanding at July 31, 2007. | 26,000 | 26,000 | |||||
Total current liabilities | 200,193 | 659,717 | |||||
Notes payable to stockholder | - | 1,970,000 | |||||
Notes payable | - | 30,000 | |||||
Total liabilities | 200,193 | 2,659,717 | |||||
Commitments and contingencies | |||||||
Stockholders' deficit: | |||||||
Series C convertible preferred stock; $1.00 par value; liquidation preference of $1,000,000; no shares issued or outstanding at July 31, 2007; 250,000 shares issued and outstanding at October 31, 2006. | - | 250,000 | |||||
Series D convertible preferred stock; $1.00 par value; liquidation preference of $500,000; no shares issued or outstanding at July 31, 2007; 250,000 shares issued and outstanding at October 31, 2006. | - | 250,000 | |||||
Common stock, $0.01 par value; 100,000,000 shares authorized; 29,990,781 and 15,732,043 shares issued and outstanding at July 31, 2007 and October 31, 2006, respectively. | 299,908 | 157,320 | |||||
Class B common stock, $0.01 par value; 839,825 shares authorized; no shares issued or outstanding at July 31, 2007; 83,983 shares issued and outstanding at October 31, 2006. | - | 840 | |||||
Additional paid-in capital | 32,284,741 | 28,464,981 | |||||
Notes receivable on common stock | - | (37,620 | ) | ||||
Accumulated deficit from previous operating activities | (27,809,201 | ) | (27,809,201 | ) | |||
Deficit accumulated during the development stage | (4,697,623 | ) | (3,798,713 | ) | |||
Total stockholders' deficit | 77,825 | (2,522,393 | ) | ||||
Total liabilities and stockholders' deficit | $ | 278,018 | $ | 137,324 |
The accompanying notes are an integral part of the condensed consolidated financial statements
2
Micro Imaging Technology, Inc. and Subsidiaries
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(Unaudited)
Cumulative period | ||||||||||||||||
from | ||||||||||||||||
November 1, 2005 | ||||||||||||||||
Three months ended | Nine months ended | through | ||||||||||||||
July 31, | July 31, | July 31, | ||||||||||||||
2007 | 2006 | 2007 | 2006 | (Unaudited) | ||||||||||||
Net Sales | $ | - | $ | - | $ | 40,000 | $ | - | $ | 40,000 | ||||||
Cost of Sales | 725 | - | 16,535 | - | 16,535 | |||||||||||
Gross profit | (725 | ) | - | 23,465 | - | 23,465 | ||||||||||
Operating costs and expenses: | ||||||||||||||||
Research and development | 109,729 | 159,785 | 614,737 | 438,188 | 1,318,739 | |||||||||||
Sales, general and administrative | 114,634 | 132,223 | 188,284 | 513,020 | 921,667 | |||||||||||
Total operating expenses | 224,363 | 292,008 | 803,021 | 951,208 | 2,240,406 | |||||||||||
Loss from operations | (225,088 | ) | (292,008 | ) | (779,556 | ) | (951,208 | ) | (2,216,941 | ) | ||||||
Other income (expense): | ||||||||||||||||
Interest income | 1,377 | 1,159 | 3,357 | 6,643 | 10,388 | |||||||||||
Interest expense | - | (37,982 | ) | (103,033 | ) | (116,780 | ) | (2,466,562 | ) | |||||||
Other income (expense), net | 800 | 3,570 | (18,078 | ) | 2,770 | (21,308 | ) | |||||||||
Other income (expense), net | 2,177 | (33,253 | ) | (117,754 | ) | (107,367 | ) | (2,477,482 | ) | |||||||
Loss from continuing operations before provision for income tax | (222,911 | ) | (325,261 | ) | (897,310 | ) | (1,058,575 | ) | (4,694,423 | ) | ||||||
Provision for income tax | - | - | (1,600 | ) | (1,600 | ) | (3,200 | ) | ||||||||
Net loss | $ | (222,911 | ) | $ | (325,261 | ) | $ | (898,910 | ) | $ | (1,060,175 | ) | $ | (4,697,623 | ) | |
Net loss per share, basic and diluted | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.04 | ) | $ | (0.08 | ) | ||||
Shares used in computing net loss per share, basic and diluted | 29,785,708 | 13,824,572 | 25,291,104 | 13,508,180 |
The accompanying notes are an integral part of the condensed consolidated financial statements.
3
Micro Imaging Technology, Inc. and Subsidiaries
(A Development Stage Company)
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Cumulative period | ||||||||||
from | ||||||||||
Nine months ended | November 1, 2005 | |||||||||
July 31, | through | |||||||||
2007 | 2006 | July 31, 2007 | ||||||||
Cash flows from operating activities: | ||||||||||
Net loss | $ | (898,910 | ) | $ | (1,060,175 | ) | $ | (4,697,623 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Depreciation | 9,100 | 7,352 | 24,762 | |||||||
Common stock issued for services | - | 109,000 | 96,000 | |||||||
Common stock issued to officers and directors for services | 175,500 | - | 446,750 | |||||||
Common stock issued for shares of subsidiary stock | - | - | 254,000 | |||||||
Common stock of subsidiary issued to employees and consultants | 2,815 | - | 2,815 | |||||||
Common stock issued as a commission | 3,683 | - | 6,683 | |||||||
Common stock issued for debt | 1,617,067 | - | 1,617,067 | |||||||
Common stock issued to former licensee | 41,319 | - | 41,319 | |||||||
Common stock issued/recovered on cancelled agreements | 20,478 | - | 20,478 | |||||||
Non-cash compensation for stock options and warrants | 31,035 | 35,250 | 76,910 | |||||||
Interest expense related to beneficial conversion feature | - | - | 1,944,800 | |||||||
Interest paid with common stock | - | 43,221 | 43,221 | |||||||
Interest on notes receivable for common stock | - | (1,029 | ) | (1,373 | ) | |||||
(Increase) decrease in assets: | ||||||||||
Notes receivable for common stock | 37,620 | - | 37,620 | |||||||
Prepaid expenses | 201 | 11,382 | 13,204 | |||||||
Inventories | (35,978 | ) | - | (35,978 | ) | |||||
Increase (decrease) in liabilities: | ||||||||||
Trade accounts payable | (18,762 | ) | (54,592 | ) | (61,065 | ) | ||||
Accounts payable to officers and directors | 15,771 | 5,616 | 11,129 | |||||||
Accrued payroll and other expenses | (456,533 | ) | (116,995 | ) | (487,695 | ) | ||||
Net cash used in operating activities | 544,406 | (1,020,970 | ) | (646,976 | ) | |||||
Cash flows from investing activities: | ||||||||||
Purchase of fixed assets | - | (119,538 | ) | (120,567 | ) | |||||
Net cash used in investing activities | - | (119,538 | ) | (120,567 | ) | |||||
Cash flows from financing activities: | ||||||||||
Principal payments on notes payable | (2,000,000 | ) | - | (2,000,000 | ) | |||||
Proceeds from issuance of notes payable | - | - | 30,000 | |||||||
Proceeds from issuance of notes payable to a related party | - | - | 100,000 | |||||||
Proceeds from issuance of common stock, net | 1,569,611 | - | 1,569,611 | |||||||
Net cash provided by financing activities | (430,389 | ) | - | (300,389 | ) | |||||
Net change in cash | 114,017 | (1,140,508 | ) | (1,067,932 | ) | |||||
Cash at beginning of period | 13,349 | 1,195,298 | 1,195,298 | |||||||
Cash at end of period | $ | 127,366 | $ | 54,790 | $ | 127,366 | ||||
Supplemental Disclosure of Cash Flow Information | ||||||||||
Interest paid | $ | 100 | $ | 469 | $ | 100 | ||||
Income taxes paid | $ | 800 | $ | 800 | $ | 800 |
The accompanying notes are an integral part of the condensed consolidated financial statements.
4
Forward-Looking Statements
This Quarterly Report on Form 10-QSB, including the Notes to the Condensed Consolidated Financial Statements and the Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intends,” “projects,” and similar expressions identify forward-looking statements. Such statements may include, but are not limited to, projections regarding demand for the Company’s products, the impact of the Company’s development and manufacturing process on its research and development costs, future research and development expenditures, and the Company’s ability to obtain new financing as well as assumptions related to the foregoing. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
1. Nature of our Business, Development Stage Company and Continuance of Operations
These unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America applicable to a going concern which contemplated the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Since inception, the Company has incurred substantial losses and there is substantial doubt that the Company will generate sufficient revenues in the foreseeable future to meet its operating cash requirements. Accordingly, the Company’s ability to continue operations depends on its success in obtaining additional capital in an amount sufficient to meet its cash needs. This raises substantial doubt about its ability to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.
Micro Imaging Technology, Inc. (formerly, Electropure, Inc.) (the “Company”), a California corporation, is a holding company whose operations are conducted through its Nevada subsidiary, Micro Imaging Technology.
In 1997, the Company began marketing a small, point-of-use water treatment product aimed at the high purity segment of commercial and industrial water treatment markets. In February 2000, the Company formed Electropure EDI, Inc. (EDI), a wholly-owned Nevada subsidiary, through which all manufacturing and sales of its proprietary water treatment products were then conducted. In October 2005, the Company sold the assets of the EDI subsidiary and discontinued operations.
The Company acquired in October 1997 an exclusive license to patent and intellectual property rights involving laser light scattering techniques to be utilized in the detection and monitoring of toxicants in drinking water. The Company formed Micro Imaging Technology (MIT) in February 2000, a wholly-owned Nevada subsidiary to conduct research and development based upon advancements developed and patented from the licensed technology. It is this technology that is being developed and is incorporated in two systems called the MIT 1000, which have recently been sold to our first customer.
The Company is developing a non-biologically based system utilizing both proprietary hardware and software to rapidly (near real time) determine the specific specie of an unknown microbe present in a fluid with a high degree of statistical probability (“MIT system”). It will analyze a sample presented to it and compare its characteristics to a library of known microbe characteristics on file. At present, it is the Company’s only operation.
Possible Acquisition of Shaanxi Zhongke Spaceflight Agriculture Development Stock Co., Ltd. (Zhongke)
In February 2007, the Company and Zhongke entered into a letter of intent to acquire Zhongke through a reverse merger share exchange transaction. The agreement provides that the Company will conduct a currently estimated 1-for-120 reverse stock split of issued and outstanding shares, including any securities associated with any outstanding options, warrants or other securities in an amount as may be required to effectively lower the issued and outstanding shares, on a fully diluted basis, to 250,000 shares immediately prior to closing the merger. Under the terms of the agreement, the Company will issue up to 81,550,000 shares of common stock to Zhongke in exchange for the payment to the Company of $480,000. Zhongke will become an indirect subsidiary of the Company and will continue its existing business under the direction of a newly appointed board of directors.
5
The Company’s existing Nevada subsidiary, Micro Imaging Technologies (MIT) conducts the Company’s remaining active business in the field of laser identification of biological hazards. Between May and July 2007, 2,815,000 shares of MIT common stock were issued at $0.001 par value to various officers, directors, key employees and consultants of the Company. The Company’s management believes that these shares have nominal current value. It recorded an expense for their issuance at par value of $2,815. As of September 12, 2007, there were 14,865,000 shares of common stock and 1,000,000 shares of convertible preferred stock issued and outstanding in the MIT subsidiary. Of such shares, the Company owns 12,000,000 shares of common stock and 1,000,000 shares of preferred stock which will be converted into additional shares of common stock sufficient to divest to the Company’s existing shareholders, on a share-for-share basis, prior to the merger.
As soon as practicable after closing, the surviving Nevada corporation, MIT, will take all steps necessary to file a Registration Statement on Form 10-SB to register the shares of MIT with the Securities and Exchange Commission and acquire a new trading symbol for the new publicly trading shares.
This proposed transaction has been approved by the Company’s Board of Directors. As of May 12, 2007, there were 29,554,666 shares of common stock and 2,600,000 shares of redeemable convertible preferred stock issued and outstanding, each share of common stock and redeemable convertible preferred stock being entitled to one vote. Of all shares entitled to vote as of May 12, 2007, 21,846,561 shares (67.9%) voted in favor of the proposal.
The Company anticipates that the transaction with Zhongke will be concluded in the Fall of 2007.
2. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting solely of normal recurring adjustments which management believes are necessary for a fair presentation of the Company’s financial position at July 31, 2007 and results of operations for the periods presented.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.
Results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with our audited financial statements and footnotes as of and for the year ended October 31, 2006, included in our Annual Report on Form 10-KSB filed with the Securities and Exchange Commission on February 15, 2007.
3. Summary of Significant Accounting Policies
The accounting policies followed are as set forth in Note 1 of the Notes to Financial Statements in the Company’s 2006 Annual Report on Form 10-KSB. The Company has not experienced any material change in its critical accounting policies since November 1, 2006. The Company’s discussion and analysis of its financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments regarding uncertainties that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, the Company evaluates its estimates, which are based upon historical experience and on other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. The Company considers the following accounting policies to be most critical in their potential effect on its financial position or results of operations.
6
Stock Based Compensation
Effective April 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards (SFAS) 123R, Share-Based Payment, which establishes accounting for equity instruments exchanged for employee services. Under the provisions of SFAS 123R, share-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant). Prior to April 1, 2006, the Company accounted for share-based compensation to employees in accordance with Accounting Principals Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. The Company also followed the disclosure requirements of SFAS 123, Accounting for Stock-Based Compensation. The Company elected to adopt the modified prospective transition method as provided by SFAS 123R and, accordingly, financial statement amounts for the prior period presented in the Form 10-QSB have not been restated to reflect the fair value method of expensing share-based compensation.
The Company recognized share-based compensation expense of $31,035 on options and warrants granted in prior periods that vested during the nine months ended July 31, 2007.
In May 1999, the Company adopted the Micro Imaging Technology, Inc. 1999 stock option plan (the “plan”), for officers, directors, employees, consultants, and advisors of the Company. The plan provides two types of options: (i) Incentive Stock Options and (ii) Non-Qualified Stock Options. The plan authorizes the granting of options up to 1,000,000 shares of common stock. The exercise price per share on options granted may not be less than the fair market value per share of the Company’s common stock at the date of grant. The exercise price per share of Incentive stock options granted to anyone who owns more than 10% of the voting power of all classes of the Company’s common stock must be a minimum of 110% of the fair market value per share at the date of grant. The options exercise price may be paid in cash or its equivalent including cashless exercises as determined and approved by the plan administrator. The term of each Incentive stock option granted is fixed by the plan administrator and shall not exceed 10 years, except that for those who own 10% of the voting power of the Company the term of the option may be no more than 5 years. Non-qualified stock options may not be granted for more than ten years. The vesting periods for both Incentive stock options and Non-qualified stock options are determined by the administrator at or after the date of grant.
Additional options have been granted outside of the Plan to employees and directors employees of the Company. Unless otherwise noted, options vest on an annual pro rata basis over various periods of time and are exercisable, upon proper notice, in whole or in part at any time upon vesting. Generally, unvested options terminate when an employee leaves the Company. The options granted have contractual lives ranging from 3 to 10 years. A summary of the activity in options granted to employees and directors of the Company as of the beginning and end of the nine months ended July 31, 2007 is presented below:
Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) | Aggregate Intrinsic Value | ||||||||||
Outstanding at November 1, 2006 | 1,270,000 | 0.25 | 5.5 | $ | 100,000 | ||||||||
Granted | — | — | |||||||||||
Exercised | — | — | |||||||||||
Expired | — | — | |||||||||||
Canceled | — | — | |||||||||||
Outstanding at July 31, 2007 | 1,270,000 | $ | 0.25 | 4.7 | $ | 89,294 |
The Company’s MIT subsidiary granted 585,000 options to various employees of the Company during the year ended October 31, 2003, 75,000 of which have expired to date. The weighted average fair value of the MIT options granted and currently outstanding is $0.10. No MIT options have been granted prior to or since fiscal 2003.
7
Summary information about the Company’s options outstanding at July 31, 2007 is set forth in the table below. Options outstanding at July 31, 2007 expire between August 2007 and January 2016.
Range of Exercise Prices | Options Outstanding July 31, 2007 | Weighted Average Remaining Contractual Life | Weighted Average Exercise Price | Options Exercisable July 31, 2007 | Weighted Average Exercise Price | |||||||||||
MICRO IMAGING TECHNOLOGY, INC: | ||||||||||||||||
$ 0.28 - $0.38 | 1,210,000 | 4.8 | $ | 0.23 | 1,020,000 | $ | 0.29 | |||||||||
$ 0.78 | 50,000 | 3.0 | $ | 0.78 | 50,000 | $ | 0.78 | |||||||||
$ 0.94 | 10,000 | 2.0 | $ | 0.94 | 10,000 | $ | 0.94 | |||||||||
1,270,000 | 1,080,000 | |||||||||||||||
MIT (SUBSIDIARY): | ||||||||||||||||
$ 0.10 | 510,000 | 1.0 | $ | 0.10 | 510,000 | $ | 0.10 | |||||||||
TOTAL: | 1,780,000 | 1,595,000 |
Total estimated unrecognized compensation from unvested stock options as of July 31, 2007 was approximately $24,700, which is expected to be recognized over a weighted average period of approximately 3.7 years.
New Accounting Pronouncements
In February 2007, the Financial Accounting Standards Board issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities”, which permits entities to choose to measure many financial instruments and certain other assets and liabilities at fair value on an instrument by instrument basis (the fair value option). The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, with early adoption permitted. The Company expects to implement the Statement as of November 1, 2008 and management believes that the adoption of SFAS No. 159 will not have a significant impact on the Company’s consolidated financial statements.
4. Securities Transactions
Private Placement Offering
In January 2007, the Company authorized a private placement offering of up to 2,000,000 shares of its common stock to qualified accredited investors at a purchase price of $0.12 per share. The offering provided for a 15% commission to Grant Bettingen, Inc., the Company’s non-exclusive selling agent. The commission is payable in a combination of 10% cash and 5% in the form of common stock at a value of $0.12 per share. During February 2007, the Company received subscriptions to this private placement offering and issued 2,144,525 shares of its common stock for net proceeds of $239,611.
On February 1, 2007, the Company authorized a second private placement offering of up to 4,000,000 shares of its common stock to qualified accredited investors at a purchase price of $0.50 per share. On February 14, 2007, one unaffiliated accredited investor purchased 2,760,000 shares of common stock in the private placement offering for net proceeds of $1,330,000. This same investor purchased 1,000,000 shares of common stock under the terms of the January 2007 private placement offering at $0.12 per share for $120,000 in proceeds to the Company.
8
Common Stock Issued for Debt
On February 14, 2007, the Company utilized proceeds received in the above private placement offerings to repay $1,000,000 in principal loans from Anthony M. Frank, our largest stockholder. Also on February 14, 2007, Mr. Frank elected to convert all remaining unpaid loans totaling $1,126,800 in principal and $406,184 in accrued interest thereon into common stock at the rate of $0.25 per share. The Company issued 6,171,553 shares of common stock pursuant to the conversion.
On April 25, 2007, the Company issued 127,824 shares of common stock at $0.25 per share upon conversion of a $30,000 principal loan, plus $1,956 in accrued interest.
On April 30, 2007, the Company issued a total of 516,479 shares of common stock to the investors of our former licensee, EDI Components. Under the terms of the 1997 agreement terminating the license of the EDI technology, which was sold in October 2005, the Company was obligated to issue shares to these individuals when the EDI assets were sold. The Company recorded a charge of $41,319 as a result of this issuance of shares.
On May 24, 2007, the Company entered into an agreement with a former officer and director to issue common stock in exchange for all past unpaid expenses, payroll and accrued vacation due him. The Company issued 211,115 shares of common stock at a fair market value of $42,223, or $0.20 per share, in cancellation of the debt. The agreement included an offset on a $37,620 note receivable due the company on common stock received by the former officer and director on the exercise of options in 1997.
Common Stock issued to Employees and Certain Consultants
During the nine months ended July 31, 2007, pursuant to his compensation arrangement, the Company issued 450,000 shares of common stock to its Chief Executive Officer, Michael W. Brennan, at prices ranging from $0.10 to $0.40 per share. The aggregate fair market value of the shares was determined to be $117,000.
The Company issued 225,000 shares of common stock to George Farquhar, its Chief Operating Officer, during the nine months ended July 31, 2007 in accordance with his compensation arrangement with the Company. The shares were issued at prices ranging from $0.10 to $0.40 per share, with an aggregate fair market value of $58,500.
On May 8, 2006, the Company granted six-year warrants to George Farquhar to purchase 250,000 shares of common for services to be rendered over a one-year period. The warrants are exercisable at $0.20 per share and vest in four equal increments each calendar quarter commencing on the date of grant. The fair market value of the 125,000 warrants that vested during the nine months ended July 31, 2007 was $21,965, or $0.18 per share, and was recorded as consulting expense. In July 2007, Mr. Farquhar surrendered these warrants in exchange for the issuance of 250,000 shares of common stock, $0.01 par value, in the Company’s privately-held Nevada subsidiary, Micro Imaging Technology.
Common Stock Exchanged for Class B Common Stock
All of the 83,983 shares of Class B common stock issued by the Company in 1986 were held in the name of Harry M. O’Hare, the Company’s founder. In connection with an order imposed by the California Corporations Commissioner at the time of the issuance, all of the Class B common shares automatically convert on a share-for-share basis into common stock upon the death of Mr. O’Hare. On or about November 13, 2006, Mr. O’Hare passed away and the Company has recorded the conversion of 83,983 shares of Class B common stock into 83,983 shares of common stock during the nine months ended July 31, 2007.
Common Stock Exchanged for Preferred Stock
On April 23, 2007, our largest shareholder, Anthony M. Frank, elected to convert all of his 250,000 shares of Series C Preferred Stock into 1,000,000 shares of common stock. Mr. Frank also converted all 250,000 shares of his Series D Preferred Stock into 500,000 shares of common stock. The conversion resulted in the aggregate reduction of 500,000 in preferred shares with a corresponding increase in common stock and additional paid-in capital.
9
Common Stock Issued/Recovered on Cancelled Agreement
In April 2007, the Company recorded the issuance of 68,259 shares of common stock at a total cost of $20,478, or $0.30 per share. The Company recorded the issuance due to the fact that it has been unable to recover a total of 77,925 shares of common stock issued to various individuals and entities in prior years pursuant to agreements that were later cancelled. The amount of shares recorded in the current year was offset by writing off a total of 8,666 shares of common stock issued and held by the Company as collateral on uncollected loans primarily due from former officers and directors.
5. Subsequent Events
In August, 2007, the Company entered into a consulting agreement with an independent contractor who will serve as Vice President of Business Development and provide sales and marketing services. The agreement provides for a payment of $12,500 per month with a future increase to $14,500 per month. In addition, the consultant will receive a total of 500,000 shares of the Company’s common stock, half of which were issued in August and half of which will issue upon the one year anniversary of the agreement.
In accordance with their consulting arrangements, on August 31, 2007, the Company issued 25,000 and 50,000 shares of common stock, respectively, to our Chief Executive Officer, Michael Brennan, and our Chief Operating Officer, George Farquhar.
On September 1, 2007, the Company entered into a one-year Distributor Agreement with Taiwan-based, Progressive Group, Inc.,. Under the agreement, the Progressive Group has the exclusive right to sell and distribute the MIT system in Taiwan and China.
On September 5, 2007, our largest shareholder, Anthony M. Frank, loaned the Company $250,000 at 12% annual interest rate. The loan is to be repaid on March 5, 2008 or from the proceeds of the sale to Zhongke, whichever occurs first.
Item 2. | Management’s Discussion and Analysis of Financial Condition and Plan of Operation. |
Certain of the statements contained herein, other than statements of historical fact, are forward-looking statements. Such forward-looking statements are based on current management expectations that involve substantial risks and uncertainties, which could cause actual results to differ materially from the results we expect. Potential risks and uncertainties that could affect our future operating results include, without limitation, economic, competitive and legislative developments.
Results of Operations
References to fiscal 2007 and fiscal 2006 are for the nine months ended July 31, 2007 and 2006, respectively.
In April 2007, the Company recorded $40,000 in revenue from the sale of its first two Micro Imaging systems (the MIT 1000) to a Seattle, Washington-based distributor for installations in and around Tokyo, Japan. The Company is in the process of purchasing additional inventory in anticipation of further near-term orders.
Cost of sales consists mainly of purchased materials associated with the assembly of the MIT 1000 product. If the MIT system gains acceptance, it is the Company’s intention to outsource the manufacturing and assembly of its products.
Since discontinuing the operations of its EDI division in October 2005, the Company’s primary operations focus on the research and development of its micro imaging technology system for detecting and identifying contaminants in fluids. As such, primarily all operating expenses are now allocated to research and development whereas in prior fiscal years, significant portions of expenses were allocated to general and administrative costs. Consequently, research and development expense for the nine month period ended July 31, 2007 increased by $176,549 compared to the prior year period and even though representative of the greatest portion of all operating expenses, does reflect slight decreases in various areas such as salaries and related expenses. Conversely, research and development expenses decreased by $50,056 for the three months ended July 31, 2007 compared to fiscal 2006, primarily reflecting a decrease in consulting expenses during the current period.
10
Sales, general and administrative expenses, for the reasons discussed above, decreased by $17,589 and $324,736 for the three and nine month periods ended July 31, 2007, respectively, compared to fiscal 2006. The reallocation of most operating expenses to research and development in fiscal 2007 and the reduction in certain expense areas as mentioned above, combine to reflect an overall decrease of $69,735 and $174,467 in the Company’s loss from operations for the three and nine months ended July 31, 2007, respectively, compared to the prior fiscal year periods.
Interest income is generated from short-term investments and decreased by $3,286 for the nine months ended July 31, 2007 as investment capital was utilized to sustain operations. For the three months ended July 31, 2007, however, interest income increased by $218 reflecting the Company’s effort to maximize its investment capital. Interest expense for the three and nine month periods ended July 31, 2007 decreased by $37,982 and $13,747, respectively, compared to the fiscal 2006 periods. The decreases reflect the effect of having converted $2 million in interest-bearing loans into common stock during the first six months of fiscal 2007.
Components of other expense, other than interest, increased by $2,770 and $20,848 for the three and nine month periods ended July 31, 2007, respectively, compared to the prior year periods. The increase mainly reflects the cost of unrecovered shares issued pursuant to agreements that were later cancelled.
We recorded the minimum state income tax provision in fiscal 2007 and 2006 as we had cumulative net operating losses in all tax jurisdictions.
Liquidity and Capital Resources
At July 31, 2007, we had a working capital deficit of $24,463, representing a $609,318 increase in working capital compared to that reported at October 31, 2006. Primarily, the increase is the consequence of the revenues realized from the sale of equity during the current period and the conversion of debt from prior year loans and accrued payroll through the issuance of common stock.
The Company recorded $40,000 in gross revenues in April 2007 on the sale of our first MIT systems. However, our primary source of income has been from loans by our majority stockholder, Anthony M. Frank, and from the sale of equity in private placement offerings. During November and December 2006, we borrowed a total of $156,800 from Anthony M. Frank. In February 2007, Mr. Frank converted all of his outstanding loans and interest into common stock. We sold 4,873,833 shares of common stock in private placement transactions for net proceeds, after commissions, of $1,569,611.
Plan of Operation
In the opinion of management, available funds and funds to be realized through the share exchange transaction with Zhongke are expected to satisfy our working capital requirements through December 2007. Our independent registered public accounting firm has included an explanatory paragraph in his report on the financial statements for the year ended October 31, 2006 included in our Annual Report on Form 10-KSB filed with the Securities and Exchange Commission on February 15, 2007 which raises substantial doubt about our ability to continue as a going concern.
We sold our first two MIT systems in April 2007 and realized gross revenues of $40,000. We are actively pursuing additional new customers for our product. In addition, we are seeking working capital through manufacturing arrangements, strategic partnerships, equity financing and/or the sale of private placement equity so that we may continue commercialization and marketing of our MIT technology. This approach is intended to optimize the value of the Company for its shareholders. To this end, we intend to seek commercial, technical and scientific partners that can aid in advancing the MIT expertise, provide external endorsements of the technology and accelerate introduction to the market. The implementation of this strategy is dependent upon our ability to identify and attract the right customers and partners over the next six-month period and to secure sufficient additional working capital in a timely manner.
On January 9, 2007, the Company entered into a non-exclusive agreement to supply MIT products to JMAR Technologies as a tandem product to their real-time water monitoring system or as a stand-alone instrument for laboratory use. JMAR is a San Diego, California based company that has a direct sales and support organization and manufactures laser-based products for multiple markets, including homeland security, the cruise ship and beverage industries, pharmaceutical companies, and municipal water utilities. To date, no sales of the MIT system have occurred under the agreement with JMAR and, although no assurances can be given that the arrangement will result in future products sales, we continue to consider the possibility of future business as promising.
11
We will be required to raise substantial amounts of new financing in the form of additional equity investments, loan financings, or from strategic partnerships, to carry out our business objectives. There can be no assurance that we will be able to obtain additional financing on terms that are acceptable to us and at the time required by us, or at all. Further, any financing may cause dilution of the interests of our current shareholders. If we are unable to obtain additional equity or loan financing, our financial condition and results of operations will be materially adversely affected. Moreover, estimates of our cash requirements to carry out our current business objectives are based upon various assumptions, including assumptions as to revenues, net income or loss and other factors, and there can be no assurance that these assumptions will prove to be accurate or that unbudgeted costs will not be incurred. Future events, including the problems, delays, expenses and difficulties frequently encountered by similarly situated companies, as well as changes in economic, regulatory or competitive conditions, may lead to cost increases that could have a material adverse effect on us and our plans. If we are not successful in obtaining financing for future developments, whether in the form of loans, licenses or equity transactions, it is unlikely that we will have sufficient cash to continue to conduct operations, particularly research and development programs, as currently planned. We believe that in order to raise needed capital, we may be required to issue debt at significantly higher interest rates or equity securities that are significantly lower than the current market price of our common stock.
No assurances can be given that currently available funds will satisfy our working capital needs for the period estimated, or that we can obtain additional working capital through the sale of common stock or other securities, the issuance of indebtedness or otherwise or on terms acceptable to us. Further, no assurances can be given that any such equity financing will not result in a further substantial dilution to the existing shareholders or will be on terms satisfactory to us.
Item 3. | Controls and Procedures |
The Company’s management has carried out an evaluation, under the supervision and with the participation of the Company’s principal executive officer and principal financial officer, of the effectiveness of the Company’s “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, the Company’s principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, (1) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
In addition, based on that evaluation, there has been no change in the Company’s internal control over financial reporting that occurred during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. | Omitted as not applicable. |
Item 2. | Changes in Securities |
On November 13, 2006, as a result of the death of the Company’s founder, Harry M. O’Hare, the Company converted his 83,983 Class B common stock into Common Stock on a one-for-one basis. The conversion is in keeping with the restrictions imposed by the California Corporation Commissioner when the shares were originally issued in 1986.
Between November 1, 2006 and July 31, 2007, the Company issued a total of 675,000 shares of common stock to the Chief Executive Officer and the Chief Operating Officer pursuant to their respective compensation arrangements. The fair market value of the stock ranged from $0.10 to $0.40 per share, for an aggregate compensation expense of $175,500 as of the nine months ended July 31, 2007.
12
During February 2007, the Company issued 2,760,000 and 2,144,525 shares of common stock at $0.50 and $0.12 per share, respectively, in private placement transactions for net proceeds of $1,559,611.
In February 2007, Mr. Anthony Frank, our largest shareholder, converted $1,542,888 in principal loans and accrued interest into 6,171,553 shares of common stock at $0.25 per share. In April of 2007, Mr. Frank also converted a total of 500,000 shares of Series C and Series D preferred stock into 1,500,000 shares of common stock.
On April 25, 2007, the Company issued 127,824 shares of common stock upon the exchange of a $30,000 loan, plus $1,956 in interest accrued on the loan. Pursuant to the terms of the note, the conversion price of the common stock was $0.25 per share.
The Company issued 516,479 shares of common stock, valued at $41,319, to the investors of the Company’s former licensee pursuant to the terms of a 1997 License Termination Agreement.
In April 2007, the Company wrote off as unrecoverable the value of 77,925 shares of common stock which it had issued pursuant to various past agreements. Concurrently, the Company cancelled 8,666 shares of common stock, which it held as collateral primarily for unpaid loans due from former officers and directors.
In May 2007, the Company issued 211,115 shares of common stock in cancellation of debt due a former officer and director. The fair market value of the shares was $42,223, or $0.20 per share.
Item 3. | Omitted as not applicable. |
Item 4. | As reported on Schedule 14C filed with the Securities and Exchange Commission on April 24, 2007, a majority of the Company’s shareholders, by written consent, approved a proposal to reincorporate in Nevada, to be effected by merging the Company with and into its wholly-owned Nevada subsidiary. |
As reported on Schedule 14C filed with the Securities and Exchange Commission on May 14, 2007, as amended through July 19, 2007, a majority of the Company’s shareholders, by written consent, approved a proposal to a) conduct a reverse stock split of its existing outstanding common shares on a basis of approximately one-for 119 shares; b) change the name of the Company to Shanxxi Zhongke Spaceflight Agriculture Development Stock Co., Inc.; c) acquire Zhongke, Inc., a space flight agricultural development company, in exchange for up to 81,550,000 shares of common stock; and d) issue to the Company’s shareholders prior to the acquisition shares in the Company’s Nevada subsidiary, Micro Imaging Technology, on a share-for-share basis.
Item 5. | Omitted as not applicable. |
Item 6. | Exhibits and Reports on Form 8-K |
(a) Exhibits: |
10.10.BZ | 12% Promissory Note with Anthony M. Frank dated September 5, 2007 * | |
31.1 | Certification of Chief Executive Officer * | |
31.2 | Certification of Chief Financial Officer * | |
32.1 | 906 Certification of Chief Executive Officer * | |
32.2 | 906 Certification of Chief Financial Officer * |
* Filed herewith (b) Reports on Form 8-K. None. |
13
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: September 12, 2007 | ||
MICRO IMAGING TECHNOLOGY, INC. | ||
By | /S/ CATHERINE PATTERSON | |
Catherine Patterson | ||
(Secretary and Chief Financial Officer with responsibility to sign on behalf of Registrant as a duly authorized officer and principal financial officer) |
14